Hospital
Riverside Middle Peninsula Hospital INC
Riverside Middle Peninsula Hospital INC was paid $19.02M by Medicaid between Jan 2018 and Dec 2024, across 203 billing codes. Its largest line is 99283, emergency room visit (moderate) — 25% of everything it billed.
33Billing provider infoRIVERSIDE MIDDLE PENINSULA HOSPITAL INC
GLOUCESTER, VA 23061
GLOUCESTER, VA 23061
33aNPI1528162534assigned 09/11/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$19.02M
24GClaims511,320
24DCodes billed203
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Virginia
Rank by total paid#33 of 80
Median peer was paid$14.69M
This provider vs. median1.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official AUSTIN, WALTER controls 12+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 48,552 | $1.10M | |
| 2019 | 66,942 | $2.24M | |
| 2020 | 71,329 | $2.55M | |
| 2021 | 84,854 | $2.98M | |
| 2022 | 74,179 | $2.48M | |
| 2023 | 91,030 | $3.79M | |
| 2024incomplete | 74,434 | $3.88M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 25% | 29,477 | 25,063 | $4.76M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 18,439 | 15,099 | $2.72M |
| 96361 | Intravenous infusion, hydration; each additional hour | 14% | 10,142 | 7,674 | $2.69M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.3% | 5,423 | 4,741 | $1.02M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.6% | 17,847 | 5,251 | $884K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 4.3% | 11,049 | 8,532 | $811K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.8% | 4,479 | 3,802 | $728K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.7% | 4,998 | 4,552 | $712K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 2.3% | 3,579 | 2,989 | $441K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.2% | 4,674 | 3,070 | $420K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.8% | 2,097 | 1,846 | $351K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.4% | 2,622 | 2,025 | $267K |
191 more codes
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,037 | $189K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,216 | $186K |
| 20610 | <1% | 1,340 | $181K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 621 | $176K |
| 97161 | <1% | 1,916 | $167K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 693 | $139K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,017 | $125K |
| G0378 | Hospital observation service, per hour | <1% | 1,016 | $118K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 4,685 | $105K |
| 80053 | Comprehensive metabolic panel | <1% | 27,096 | $102K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,340 | $95K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 989 | $92K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 4,342 | $90K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,811 | $90K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,149 | $89K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,402 | $89K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 454 | $77K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 227 | $74K |
| 76642 | <1% | 519 | $61K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 264 | $51K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 69 | $51K |
| 93971 | <1% | 422 | $45K | |
| 73030 | <1% | 2,267 | $42K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 685 | $38K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 14,985 | $35K |
| 97162 | <1% | 210 | $32K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,372 | $32K |
| 73630 | <1% | 1,793 | $29K | |
| 72100 | <1% | 1,197 | $29K | |
| 73610 | <1% | 1,706 | $29K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 30,352 | $28K |
| 71271 | <1% | 210 | $23K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 42 | $23K |
| 73130 | <1% | 1,189 | $22K | |
| 71045 | Radiologic examination, chest; single view | <1% | 10,662 | $21K |
| 73560 | <1% | 1,218 | $20K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 11,426 | $20K |
| 81025 | <1% | 3,394 | $19K | |
| 73564 | <1% | 576 | $19K | |
| 73562 | <1% | 1,306 | $19K | |
| 93017 | <1% | 107 | $18K | |
| 73110 | <1% | 885 | $17K | |
| 72040 | <1% | 551 | $17K | |
| 71250 | <1% | 309 | $16K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 80 | $16K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,902 | $16K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 27 | $16K |
| 87040 | <1% | 2,851 | $15K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 803 | $14K |
| 36415 | Collection of venous blood by venipuncture | <1% | 12,250 | $11K |
| 83880 | <1% | 1,817 | $11K | |
| 84484 | <1% | 11,255 | $10K | |
| 73502 | <1% | 497 | $8K | |
| J3490 | Unclassified drugs | <1% | 9,817 | $7K |
| 90715 | <1% | 341 | $7K | |
| 74018 | <1% | 426 | $7K | |
| 97750 | <1% | 341 | $7K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 26 | $6K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,008 | $5K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,534 | $5K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,836 | $5K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 61 | $5K |
| 12001 | <1% | 26 | $5K | |
| 85379 | <1% | 1,124 | $5K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,807 | $5K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,028 | $4K |
| 76830 | Ultrasound, transvaginal | <1% | 29 | $4K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 140 | $4K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,902 | $3K |
| 76775 | <1% | 41 | $3K | |
| 20550 | <1% | 15 | $3K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,828 | $3K |
| 70491 | <1% | 16 | $3K | |
| 86756 | <1% | 538 | $3K | |
| 72141 | <1% | 14 | $3K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,634 | $3K |
| 73080 | <1% | 96 | $2K | |
| 83735 | <1% | 5,250 | $2K | |
| 70486 | <1% | 25 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 855 | $2K |
| 00811 | <1% | 159 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,158 | $2K |
| 97116 | <1% | 79 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 528 | $2K |
| 83605 | <1% | 3,474 | $2K | |
| 81001 | <1% | 14,314 | $2K | |
| 77080 | <1% | 39 | $2K | |
| 80047 | <1% | 576 | $2K | |
| 86885 | <1% | 757 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 11,312 | $1K |
| 76536 | <1% | 12 | $1K | |
| 85610 | <1% | 3,696 | $1K | |
| 51798 | <1% | 448 | $1K | |
| 80061 | Lipid panel | <1% | 541 | $1K |
| 80143 | <1% | 166 | $1K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 13 | $1K |
| 87081 | <1% | 2,546 | $1K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,904 | $1K |
| 72110 | <1% | 102 | $1K | |
| 86900 | <1% | 998 | $1K | |
| 73590 | <1% | 83 | $1K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,659 | $1K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,906 | $995.99 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 10,634 | $967.71 |
| 82947 | <1% | 4,162 | $893.31 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 53 | $666.80 |
| 96367 | <1% | 38 | $666.54 | |
| J2704 | Injection, propofol, 10 mg | <1% | 7,045 | $651.51 |
| 86901 | <1% | 998 | $646.29 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 98 | $642.52 |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 26 | $616.53 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 594 | $586.33 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 672 | $573.33 |
| 94060 | <1% | 17 | $565.96 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 107 | $552.62 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 62 | $531.60 |
| 86140 | <1% | 134 | $520.92 | |
| 36430 | <1% | 22 | $517.90 | |
| 84703 | <1% | 2,495 | $498.51 | |
| 84145 | <1% | 239 | $468.70 | |
| 82077 | <1% | 2,584 | $454.76 | |
| 80179 | <1% | 110 | $453.39 | |
| 82565 | <1% | 741 | $448.11 | |
| 87077 | <1% | 2,820 | $407.00 | |
| 83690 | <1% | 6,221 | $404.26 | |
| 73140 | <1% | 40 | $368.50 | |
| 85652 | <1% | 238 | $332.96 | |
| 85730 | <1% | 1,299 | $309.89 | |
| 73552 | <1% | 51 | $283.88 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,908 | $251.28 |
| 85014 | <1% | 1,293 | $251.15 | |
| 73501 | <1% | 15 | $251.02 | |
| 80069 | <1% | 111 | $239.80 | |
| 87430 | <1% | 2,741 | $228.51 | |
| 87186 | <1% | 2,552 | $217.87 | |
| 94727 | <1% | 17 | $213.36 | |
| 94729 | <1% | 17 | $213.36 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,442 | $194.67 |
| 73090 | <1% | 14 | $168.75 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 819 | $151.95 |
| 81002 | <1% | 941 | $140.35 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,060 | $139.27 |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,705 | $125.40 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,095 | $103.34 |
| 81003 | <1% | 1,323 | $80.07 | |
| 84439 | <1% | 46 | $76.85 | |
| 84702 | <1% | 30 | $63.47 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 766 | $60.67 |
| A9150 | Non-prescription drugs | <1% | 24,616 | $60.04 |
| 71101 | <1% | 13 | $59.27 | |
| 36592 | <1% | 300 | $59.08 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 822 | $53.11 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 613 | $49.74 |
| 82607 | <1% | 17 | $48.42 | |
| 85018 | <1% | 77 | $33.33 | |
| 00731 | <1% | 145 | $25.16 | |
| 87205 | <1% | 93 | $17.20 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 357 | $16.75 |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 235 | $12.87 |
| J1815 | Injection, insulin, per 5 units | <1% | 136 | $12.21 |
| 82803 | <1% | 126 | $12.02 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 539 | $11.27 |
| 82550 | <1% | 80 | $10.66 | |
| 96376 | <1% | 1,988 | $8.97 | |
| 87070 | <1% | 14 | $8.60 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 281 | $8.37 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 109 | $6.80 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 77 | $5.80 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 38 | $4.56 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 46 | $2.40 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 71 | $2.20 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 15 | $1.88 |
| A9270 | Non-covered item or service | <1% | 5,141 | $0.06 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 28 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 30 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 97 | $0.00 |
| A4351 | Intermittent urinary catheter; straight tip, with or without coating (teflon, silicone, or silicone elastomer, etc.), each | 0% | 379 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 106 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 45 | $0.00 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 0% | 62 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 133 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 3,427 | $0.00 |
| 87210 | 0% | 23 | $0.00 | |
| 00812 | 0% | 150 | $0.00 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 739 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 36 | $0.00 |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | 0% | 16 | $0.00 |
| A6402 | Gauze, non-impregnated, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | 0% | 47 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 18 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 23 | $0.00 |
| 84100 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialAUSTIN, WALTER (SENIOR VICE PRESIDENT/CFO)
| Provider | Location | Paid |
|---|---|---|
| Riverside Hospital INC | Newport News, VA | $136.80M |
| Shore Health Services INC. | Onancock, VA | $24.72M |
| Doctors' Hospital of Williamsburg | Williamsburg, VA | $11.99M |
| Riverside Hospital INC | Newport News, VA | $4.48M |
| Patrick Henry Hospital, INC. | Newport News, VA | $1.52M |
| Shore Health Services, INC | Accomac, VA | $1.31M |
| Riverside Hospice and Homecare Services LLC | Warsaw, VA | $438K |
| Riverside Hospital INC | Newport News, VA | $412K |
| Riverside Middle Peninsula Hospital INC | Gloucester, VA | $37K |
| Riverside Hospital, INC | Newport News, VA | $6K |
| Patrick Henry Hospital, INC. | West Point, VA | $4K |
| Shore Health Services INC | Accomac, VA | $1K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.